Role of serotonin drugs in the treatment of social phobia

J Clin Psychiatry. 1997:58 Suppl 5:50-4.

Abstract

Social phobia is a common anxiety disorder that is underdiagnosed and undertreated. To date, three classes of serotonin drugs have been used to treat patients suffering from social phobia. These include the serotonin selective reuptake inhibitors (SSRIs), the partial 5-HT1A agonist buspirone, and the 5-HT3 antagonist ondansetron. Although none of the serotonin agents have yet been directly compared with the gold standard monoamine oxidase inhibitor phenelzine or the high potency triazolobenzo-diazepines alprazolam or clonazepam, the SSRIs, as a class, appear to be clinically useful agents. Further studies using larger sample sizes and double-blind methodology are needed to clarify the role of serotonin drugs in the treatment of social phobia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Buspirone / therapeutic use
  • Clinical Trials as Topic
  • Double-Blind Method
  • Fluvoxamine / therapeutic use
  • Humans
  • Ondansetron / therapeutic use
  • Phobic Disorders / drug therapy*
  • Phobic Disorders / psychology
  • Placebos
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin Agents / therapeutic use*
  • Treatment Outcome

Substances

  • Placebos
  • Serotonin Agents
  • Serotonin Uptake Inhibitors
  • Ondansetron
  • Fluvoxamine
  • Buspirone